altarboy40, they are definitely headed that way fast...
According to Dr. Janet Woodcock, Deputy Director for Operations at FDA, "FDA's efforts will bring us one step closer to 'personalizing' medical treatment." She added, "We hope ultimately to bring pharmacogenomics . . . to every healthcare professional's prescription pad for the benefit of their patients and U.S. consumers." Personalized medicine, according to the FDA, will eventually replace "the standard hit-or-miss approach to treating patients."
Soon after the FDA announcement, the Personalized Medicine Coalition (PMC), of which DNAPrint is a member, issued its own release applauding the guidelines as "paving the way to a new generation of diagnostics and therapeutics." The agency noted "that our members are looking forward to additional protocols, specifically those on the co-development of pharmacogenomic diagnostics and therapeutics and on the use of micro-arrays in DNA analysis.
From the vantage point of the future, today's FDA announcement is likely to be regarded as a milestone in drug discovery and development that will help lead to a new generation of medicine and healthcare, that of tailoring treatment to the individual based on his or her genetic and molecular makeup".
Market Data 
Markets 
AI
